Cite
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
MLA
Koshkin, Vadim S., et al. “Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma.” Journal for Immunotherapy of Cancer, vol. 6, no. 1, Jan. 2018, p. 9. EBSCOhost, https://doi.org/10.1186/s40425-018-0319-9.
APA
Koshkin, V. S., Barata, P. C., Zhang, T., George, D. J., Atkins, M. B., Kelly, W. J., Vogelzang, N. J., Pal, S. K., Hsu, J., Appleman, L. J., Ornstein, M. C., Gilligan, T., Grivas, P., Garcia, J. A., & Rini, B. I. (2018). Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. Journal for Immunotherapy of Cancer, 6(1), 9. https://doi.org/10.1186/s40425-018-0319-9
Chicago
Koshkin, Vadim S, Pedro C Barata, Tian Zhang, Daniel J George, Michael B Atkins, William J Kelly, Nicholas J Vogelzang, et al. 2018. “Clinical Activity of Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma.” Journal for Immunotherapy of Cancer 6 (1): 9. doi:10.1186/s40425-018-0319-9.